News Medical5h
Sotagliflozin could be used to reduce the risk of deadly cardiovascular events, trial shows
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...
MedPage Today10h
SGLT1/2 Inhibitor Cut Stroke, Heart Attack Risk in Diabetic Kidney Disease
The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...
Research shows sotagliflozin is the first medication of its kind to significantly reduce both heart attacks and strokes
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...
EurekAlert!1d
A diabetes, heart failure, and kidney disease medication is the first of its kind to significantly reduce both heart attacks and strokes
Study led by Mount Sinai researcher shows sotagliflozin is the only drug in its class to demonstrate these results ...